JP2001513111A - 腫瘍付随血管（ｔｕｍｏｒ−ａｓｓｏｃｉａｔｅｄ ｂｌｏｏｄ ｖｅｓｓｅｌｓ）上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート - Google Patents

腫瘍付随血管（ｔｕｍｏｒ−ａｓｓｏｃｉａｔｅｄ ｂｌｏｏｄ ｖｅｓｓｅｌｓ）上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート

Info

Publication number
JP2001513111A
JP2001513111A JP53859598A JP53859598A JP2001513111A JP 2001513111 A JP2001513111 A JP 2001513111A JP 53859598 A JP53859598 A JP 53859598A JP 53859598 A JP53859598 A JP 53859598A JP 2001513111 A JP2001513111 A JP 2001513111A
Authority
JP
Japan
Prior art keywords
vpf
antibody
vivo
binding
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP53859598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001513111A5 (https=
Inventor
センガー，ドナルド・アール
ドボラク，ハロルド・エフ
Original Assignee
ベス・イスラエル・デイーコネス・メデイカル・センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベス・イスラエル・デイーコネス・メデイカル・センター filed Critical ベス・イスラエル・デイーコネス・メデイカル・センター
Publication of JP2001513111A publication Critical patent/JP2001513111A/ja
Publication of JP2001513111A5 publication Critical patent/JP2001513111A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP53859598A 1997-03-03 1998-02-26 腫瘍付随血管（ｔｕｍｏｒ−ａｓｓｏｃｉａｔｅｄ ｂｌｏｏｄ ｖｅｓｓｅｌｓ）上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート Ceased JP2001513111A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/807,992 US6022541A (en) 1991-10-18 1997-03-03 Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
US08/807,992 1997-03-03
PCT/US1998/003765 WO1998039037A1 (en) 1997-03-03 1998-02-26 Concurrent in-vivo immunoconjugate binding to multiple epitopes of vascular permeability factor on tumor-associated blood vessels

Publications (2)

Publication Number Publication Date
JP2001513111A true JP2001513111A (ja) 2001-08-28
JP2001513111A5 JP2001513111A5 (https=) 2005-10-06

Family

ID=25197602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53859598A Ceased JP2001513111A (ja) 1997-03-03 1998-02-26 腫瘍付随血管（ｔｕｍｏｒ−ａｓｓｏｃｉａｔｅｄ ｂｌｏｏｄ ｖｅｓｓｅｌｓ）上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート

Country Status (6)

Country Link
US (1) US6022541A (https=)
EP (1) EP0968002A4 (https=)
JP (1) JP2001513111A (https=)
AU (1) AU722722B2 (https=)
CA (1) CA2283295C (https=)
WO (1) WO1998039037A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504092A (ja) * 2007-10-25 2011-02-03 ユニバーシティ オブ ブリストル 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6824986B1 (en) * 1997-10-06 2004-11-30 University Of Cincinnati Methods for measuring in vivo cytokine production
IL128852A0 (en) * 1999-03-05 2000-01-31 Compugen Ltd Novel nucleic acid and amino acid sequences
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
JP4343473B2 (ja) * 1999-06-21 2009-10-14 日本メジフィジックス株式会社 血漿蛋白質に結合親和性を有する薬剤の投与方法並びに当該投与方法に用いられる製剤
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
FR2799465B1 (fr) * 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
US6974791B2 (en) * 2000-03-16 2005-12-13 The University Of Pittsburgh Endothelial specific targeting
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
AU2002362646A1 (en) * 2001-10-09 2003-04-22 The Johns Hopkins University A phosphatase associated with metastasis
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US8080253B2 (en) * 2004-02-05 2011-12-20 The Ohio State University Research Foundation Chimeric VEGF peptides
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514505A (en) * 1982-05-21 1985-04-30 The Trustees Of Columbia University In The City Of New York Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays
WO1993008210A1 (en) * 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
AU702250B2 (en) * 1994-07-11 1999-02-18 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504092A (ja) * 2007-10-25 2011-02-03 ユニバーシティ オブ ブリストル 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体

Also Published As

Publication number Publication date
WO1998039037A1 (en) 1998-09-11
AU722722B2 (en) 2000-08-10
US6022541A (en) 2000-02-08
AU6757098A (en) 1998-09-22
EP0968002A1 (en) 2000-01-05
CA2283295C (en) 2007-12-04
EP0968002A4 (en) 2008-03-26
CA2283295A1 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
JP2001513111A (ja) 腫瘍付随血管（ｔｕｍｏｒ−ａｓｓｏｃｉａｔｅｄ ｂｌｏｏｄ ｖｅｓｓｅｌｓ）上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート
US7687607B2 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLS)
JP3698370B2 (ja) 癌腫抗原用抗体
CA1309340C (en) Cationized antibodies for delivery through the blood-brain barrier
US6548066B1 (en) Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
JPH025893A (ja) 新規抗体
RU2008141912A (ru) Противоопухолевые лекарства на основе антител к клеточным антигенам
JP2005527488A (ja) Ｍｅｔを発現し、肝細胞増殖因子と結合する腫瘍のモノクローナル抗体画像化および治療
JPH05500600A (ja) スフィンゴ糖脂質に対する免疫応答を誘導する抗イディオタイプ抗体及びその使用
JP2006523607A (ja) Ｃｃｋ−ｂ／ガストリン受容体に対する免疫原性組成物および腫瘍の治療法
JPH07506484A (ja) カルチノーマ関連抗原（ｓｋ１），ｓｋ１に対するモノクローナル抗体，これら抗体を産生する方法及びその使用
US7153506B2 (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
JPH01501476A (ja) 抗体、抗体断片、ホルモン並びに他の標的剤、およびそれらの配合体を標的とする改良方法
JPS60190796A (ja) 脳特異的なｍＲＮＡから翻訳されたプロテイノイドの部分に対応する合成ポリペプチド、これを用いた受容体、方法及び診断系
Billings et al. Monoclonal antibodies against Opisthorchis viverrini antigens
CA2614782A1 (en) Concurrent in-vivo immunoconjugate binding to multiple epitopes of vascular permeability factor on tumor-associated blood vessels
JPH02242672A (ja) ニユーロペプチドｙに対する単クローン抗体およびその製造方法
JPH07508287A (ja) 免疫応答を変調する方法および薬剤，並びにその使用
Mulshine et al. Lung cancer markers as detected by monoclonal antibodies
JPH04218388A (ja) ソマトトロピン結合蛋白質を特異的に認識する抗体
MXPA99010424A (en) Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
CZ399899A3 (cs) Imunogenní preparáty k receptoru pro CCKB/gastrin a metody léčby nádorů

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050208

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080507

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081118